Ifosfamide pharmacokinetics and neurotoxicity

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Clinical pharmacology and therapeutics·2017

Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer.

Veterinary and comparative oncology·2012

An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.

Clinical pharmacology and therapeutics·2010

Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.

International journal of clinical pharmacology and therapeutics·2009

Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells.

Human & experimental toxicology·2008

Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.

Leukemia·2007

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Respiratory Depressant Interactions of Fentanyl and Xylazine and Their Reversal by Naloxone and Yohimbine in Mice.

Neuropharmacology·2026

Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B.

JHEP reports : innovation in hepatology·2026

Syringeable hyaluronic acid-based hydrogel co-loaded with Cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy.

Biomedical materials (Bristol, England)·2026

Yunnan Baiyao inhibits EBV-positive nasopharyngeal carcinoma via ferritinophagy-dependent ferroptosis.

Tissue & cell·2026

Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis.

Journal of biochemical and molecular toxicology·2026

Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes.

Annals of surgical oncology·2026

Related Experiment Videos

Ifosfamide pharmacokinetics and neurotoxicity

Related Concept Videos

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer.

An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.

Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.

Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells.

Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Respiratory Depressant Interactions of Fentanyl and Xylazine and Their Reversal by Naloxone and Yohimbine in Mice.

Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B.

Syringeable hyaluronic acid-based hydrogel co-loaded with Cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy.

Yunnan Baiyao inhibits EBV-positive nasopharyngeal carcinoma via ferritinophagy-dependent ferroptosis.

Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis.

Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes.

Related Experiment Videos

Ifosfamide pharmacokinetics and neurotoxicity

Related Concept Videos

Related Articles